Press Releases.

-Oral presentation during general session on interim RG-101 Phase II results & three posters to be presented-

- RG-101 Containing Regimen Has Potential to Reduce Harvoni®, Olysio®, or Daklinza™ Rx to 4 Week Duration -

- Additional studies on track for enrollment in H12016 with multiple data read-outs expected throughout 2016 -

-Regulus Earns $10.0 Million Milestone Payment from AstraZeneca and Achieves Key Goal for 2015-

-Expanded Development of RG-101 through Clinical Trial Collaboration with GSK to Achieve Potential Single Visit HCV Therapy -

- Long-Acting Parenteral Formulation of GSK2878175 Being Developed; Co-Administration with RG-101 May Enable Single Visit Therapy for HCV Patients

RG-012 Shown to Directly Inhibit microRNA-21, Demonstrates Favorable Preclinical Profile Supporting Proof of Mechanism and Clinical Development

-Phase I Clinical Data will be Featured in Viral Hepatitis Plenary Session-

-Advanced 'Clinical Map Initiative' with Start of Key Clinical Trials for RG-101 and RG-012-

-Achieves Key 'Clinical Map Initiative' Goal for 2015 and Advances Orphan Disease Efforts-

- Paul Grint, M.D. Appointed as President and Chief Executive Officer and as a Member of the Board of Directors-

- Advanced 'Clinical Map Initiative' with Positive Results on RG-101 and Selection of RG-125 as 3rd Clinical Candidate -

-RG-101 Achieves Sustained HCV Viral Suppression with Favorable Safety and Tolerability-